AGTR1 and lung cancer: Patients with non–small-cell lung cancer who were undergoing first-line platinum-based chemotherapy experienced longer median survival if they were receiving a concomitant RASi or AT1R blocker (11.7 vs 8.6 mo; hazard ratio [HR] 0.56; p = 0.03) [24].